Appln No.: 10/646,436

Amendment Dated: February 16, 2006 Reply to Office Action of January 9, 2006

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (previously presented) An RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin.
- 2. (previously presented) The RNA molecule of claim 1, wherein the sequence of bases complementary to the gene encoding human clusterin has a length of 19 to 21 nucleotides.
- 3. (previously presented) The RNA molecule of claim 2, wherein the sequence of bases complementary to the gene encoding human clusterin has a length of 19 nucleotides.
- 4. (currently amended) The RNA molecule of claim 3, wherein the RNA molecule consists of a sequence selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.
- 5-9. (canceled)
- 10. (previously presented) A pharmaceutical composition comprising an RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin, together with a pharmaceutically acceptable carrier.
- 11. (original) The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable carrier is a sterile injectable solution.
- 12. (previously presented) The pharmaceutical composition of claim 11, wherein the sequence of bases complementary to the gene encoding human clusterin has a length of 19 to 21 nucleotides.
- 13. (previously presented) The pharmaceutical composition of claim 12, wherein the sequence of bases complementary to the gene encoding human clusterin has a length of 19 nucleotides.

Appln No.: 10/646,436

Amendment Dated: February 16, 2006 Reply to Office Action of January 9, 2006

- 14. (currently amended) The pharmaceutical composition of claim 13, wherein the RNA molecule consists of a sequence selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.
- 15-19. (canceled).
- 20. (withdrawn) A method of treating a cancer that expresses clusterin, comprising administering to an individual in need of treatment an RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin.
- 21. (withdrawn) The method of claim 20, wherein the sequence of bases complementary to the gene encoding human clusterin has a length of 19 nucleotides.
- 22. (canceled)
- 23. (withdrawn, currently amended) The method of claim 22, wherein the RNA molecule consists of sequence selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.
- 24-28. (canceled)
- 29. (withdrawn) The method of claim 20, wherein the cancer is selected from the group consisting of sarcomas, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma.
- 30. (canceled)
- 31. (previously presented) The RNA molecule of claim 1, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.
- 32. (withdrawn) The RNA molecule of claim 1, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 68.
- 33. (previously presented) The pharmaceutical composition of claim 10, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.
- 34. (withdrawn) The pharmaceutical composition of claim 10, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 68.